About: Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in phase 2b clinical trial for pancreatic cancer; and treatment of ovarian cancer. It also develops AMP886 for application in oncology and chronic fibrosis indications. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.
Sector: Healthcare
Industry: Biotechnology
Latest price: A$0.11 (-4.35%)
ATX ASX Amplia Therapeutics Ltd
Amplia Therapeutics Ltd share price
ATX price activity
Último preço
$ 0,110
Variação (24h)
-0,01 AUD (-4,35%)
Volume
76.28K
Volume (média 4 sem.)
-
Abertura
$ 0,12
Variação do dia
$ 0,11 - $ 0,12
Fechamento anterior
$ 0,12
Último negócio
07 Oct, 12:57 am GMT+0
Atrasado
07 Oct, 12:57 am GMT+0
ATX price performance
Atrasado
07 Oct, 12:57 am GMT+0
quote.marketSignals